Health Professionals
Patients & Families
Careers 
R&D PIPELINE & CLINICAL PROGRAMS
Advancing next-generation cellular & gene therapies
CARA Yakhteh is building a deep, scientifically diversified pipeline aimed at life-threatening hematologic malignancies and severe genetic hemoglobin disorders. By harnessing autologous cell engineering, synthetic immunology, and CRISPR-based genome editing, we translate frontier biology into clinical reality.
Explore our investigational programs below to review the disease biology, targeted molecular mechanisms, and prospective development pathways.
Investigational Programs in Focus
Our active research and development portfolio focused on relapsed hematologic cancer and congenital blood disorders.
BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma
Autologous T cells engineered to express a chimeric antigen receptor recognizing B-cell maturation antigen (BCMA), directing personalized cytotoxic responses toward malignant plasma cells.
CRISPR-Based Therapy for β-Thalassemia & Sickle Cell
Ex vivo genome editing of autologous hematopoietic stem cells targeting the BCL11A erythroid enhancer to downregulate fetal hemoglobin suppression and restore functional oxygen transport.